Immunocytochemical localization of an immunoconjugate (antibody IgG against prostatic acid phosphatase conjugated to 5-fluoro-2'-deoxyuridine) in human prostate tumors

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1385-1392

  Sinha, Akhouri A ^a,b,c   Quast, Barry J ^a   Wilson, Michael J ^a,b   Reddy, Pratap K ^a,b   Fernandes, Eduardo T ^a,b   Ewing, Stephen L ^a,b   Gleason, Donald F ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c VA MEDICAL CENTER   (United States)

Author keywords

Confocal microscopy; Human prostate cancer; Immunoconjugate specificity; Immunofluorescence; Immunohistochemistry; Organ culture

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIBODY CONJUGATE; FLOXURIDINE; FLUORESCEIN ISOTHIOCYANATE; IMMUNOGLOBULIN G ANTIBODY;

ARTICLE; COLON; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; KIDNEY; KIDNEY PARENCHYMA; MALE; ORGAN CULTURE; PRIORITY JOURNAL; PROSTATE; PROSTATE EPITHELIUM; PROSTATE TUMOR;

ACID PHOSPHATASE; ANIMALS; COLON; EPITHELIAL CELLS; FLOXURIDINE; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOTOXINS; INTESTINAL MUCOSA; KIDNEY; MALE; NEOPLASM INVASIVENESS; PROSTATE; PROSTATIC NEOPLASMS; RABBITS;

EID: 0031830465     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Metlin C: The American cancer society national prostate cancer detection project and national patterns of prostate detection and treatment. CA Cancer J Clin 47: 265-275,1997.
2. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics. CA Cancer J Clin 47: 5-27, 1997.
3. Garnick MB: Prostate cancer: screening, diagnosis, and management. Ann Inter Med 118: 804-818, 1993.
4. Davidson PJT. Hop W, Kurth KH, Fossa SD, Hakon W, Schroder FH, and the European Organization for Research and Treatment of Cancer Genitourinary Group: Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stages to 4, N1 to 3, MO, D1). J Urol 154: 2118-2122, 1995.
5. Wernert N, Bieroff E, and Hugel A: Pathological aspects of prostate cancer and benign nodular hyperplasia. Anticancer Res 17: 2907-2910, 1997.
6. Partin AW, Kattan MW, Subong ENP, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, and Pearson JD: Combination of prostate-specific antigen, clinical stage, Gleason score to predict pathological stage of localized prostate cancer. JAMA 277: 1445-1451, 1997.
7. Blumenstein B, Crawford DE, Saiers JH, Stephens RL, Rivkin SE, and Coltman. Jr C A: Doxorubicin, mitomycin and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A southwest oncology group study. J Urol 150: 411-413, 1993.
8. Pietersz GA, Rowland A, Smyth MJ, and Mckenzie IFC: Chemoimmunoconjugates for the treatment of cancer. Adv Immunol 56: 301-387, 1994.
9. Crawford ED, DeAntonio EP, Labrie F, Schroder FH, and Geller J: Therapeutic controversies: Endocrine therapy of prostate cancer. J Clin Endocrin Metabol 80: 1062-1078, 1995.
10. Huang C-L, Brassil D, Rozzell M, Schellhammer PF, and Wright Jr GL: Comparison of prostate secretory protein and prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. The Prostate 23: 201-212, 1993.
11. Lowe FC, and Trauzzi SJ: Prostatic acid phosphatase in 1993: Its limited clinical utility. Urol Clin North America 20: 589-595, 1993.
12. Oesterling JE: Prostate specific antigen. Cancer 75: 1795-1804, 1995.
13. Ostrowski WS, and Kuciel R: Human prostatic acid phosphatase: selected properties and practical applications. Clin Chim Acta 226: 121-129, 1994.
14. McCormack RT, Wang TJ, Rittenhouse HG, Wolfert RL, Finlay JA, Lilja H, Sokoloff RL, and Oesterling JE: Molecular forms of prostatic-specific antigen and the human kallikrein gene family: A new era. Urology 45: 729-744, 1995.
15. Brawn PN, Jay DW, Foster DM, Kuhl D, Speights VO, Johnson EH, Riggs M, Lind ML, Coffield KS, and Weaver B: Prostatic acid phosphatase levels (enzymatic method) from completely sectioned, clinically benign, whole prostates. The Prostate 28: 295-299, 1996.
16. Abrahamsson PA, Lilja H, and Oesterling JE: Molecular forms of serum prostate-specific antigen. Urol. Clin. North America 24: 353-365, 1997.
17. Chu T. M: Prostate-specific antigent and early detection of prostate cancer. Tumor Biol 18: 123-134, 1997.
18. Smith Jr. JA, Lange, PH, Janknegt RA, Abbou CC, and deGery A: Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol 157: 1329-1334, 1997.
19. Sinha AA, Hagen KA, Sibley RK, Wilson MJ, Limas C, Reddy PK, Blackard CE, and Gleason DF: Analysis of fixation effects on immunohistochemical localization of prostatic specific antigen in human prostate. J Urol 136: 722-727, 1986.
20. Sinha AA, Wilson, MJ, and Gleason DF: Immunoelectron microscopic localization of prostatic specific antigen in human prostate by the protein A-gold complex. Cancer 60: 1288-1293, 1987.
21. Sinha AA, Gleason DF, Wilson MJ, Wick MR, Reddy PK, and Blackard CE: Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the Gleason Grading system. Prostate 13: 1-15, 1988.
22. Culkin DJ, Gelder FB, Mata JA, Zitman RI, and Venable DD: Cellular PSA in benign and malignant prostate. The Prostate 26: 1-4, 1995.
23. Katz AE, DeVries GM, Olsson CA, Benson MC, Swanton P, Ikeguchi EF, and Butryan R: Molecular staging of genitourinary malignancies. Urology 47: 948-958, 1996.
24. Murphy GP, Troychak MJ, Cobb OE, Bowes VA, Kenny RJ, Barren III RJ, Kenny GM, Ragde H, Holmes EH, and Wolfert RL: Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer. The Prostate 33: 141-146, 1997.
25. Bunting PS: A guide to the interpretation of serum prostate specific antigen levels. Clin Biochem 28: 221-241, 1995.
26. Ljung G, Norberg M, Holmberg L, Busch C, and Nilsson S: Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; Immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8. The Prostate 31: 91-97, 1997.
27. Sinha AA, Sackrison JL, DeLeon OF, Wilson MJ, and Gleason DF: Antibody immunoglobulin (IgG) against human prostatic specific antigen (PSA) as a carrier protein for chemotherapeutic drugs to human prostatic tumors: Part 1. A double immunofluorescence analysis. Anat Rec 245: 652-661, 1996.
28. Pretlow T, Yang GB, and Pretlow TP: Organ culture of benign, aging, and hyperplastic human prostate. Microsc Res Techniques 30: 271-281, 1995.
29. Whiteley J, Jerkunica I, and Deits T: Thymidine synthetase from Amethopteri-Resistant Lactobacillis casei. Biochem 13: 2044-2050, 1974.
30. Gleason DF: Histologic grading of prostate cancer. Hum Pathol 23: 273-279, 1992.
31. Goerlach A, Krauer KG, McKenzie IFC, and Pietersz GA: In vitro antitumor activity of 2'-deoxy-5-fluorouridine-monoclonal antibody conjugates. Bioconjugate Chem 2: 96-101, 1991.
32. DeGuchi T, Chu TM, Leong SS, Horozsewicz JS, and Lee CL: Potential therapeutic effect of adriamycin-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor. J Urol 137: 353-358, 1987.
33. Goldenberg DM, DeLand FH, Bennett SJ, Primus FJ, Nelson O, Flanigan RC, McRoberts JW, Bruce AW, and Mahan DE: Radioimmunodetection of prostate cancer. JAMA 250: 630-635, 1983.
34. Vihko P, Heikkila J, Kontturi M, Wahlberg L, and Vihko R: Radioimaging of the prostate and metastases of prostatic carcinoma with 99m Tc-labelled prostatic acid phosphatase-specific antibodies and their Fab fragments. Ann Clin Res 16: 51-52, 1984.
35. Leroy M, Teillac P, Rain JD, Saccavini JC, LeDuc A, and Najean Y: Radioimmunodetection of lymph node invasion in prostatic cancer. Cancer 64: 1-5, 1989.
36. Babaian RJ, Murray JL, Lamaki LM, Haynie TP, Hersh EM, Rosenbum MG, Glenn HL, Unger MW, Carlo DJ, and vonEschenbach AC: Radioimmunological imaging of metastatic prostatic cancer with 111 indium-labeled monoclonal antibody PAY 276. J Urol 137: 439-443, 1987.
37. Meyers FJ, Denardo SJ, Macey D, White RD, and Unger M: Deverlopment of monoclonal antibody imaging of metastatic prostatic carcinoma. The Prostate 14: 209-220, 1989.
38. 111I-labelled monoclonal antibody PAY 276 for the detection of pelvic nodal metastases in prostatic carcinoma. Eur J Nucl Med 16: 149-156, 1990.
39. Karr JF, Kantor JA, Hand PH, Eggensperger DL, and Schlom J: The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line. Cancer Res 55: 2455-2462, 1995.
40. Simak R, Madersbacher S, Zhang ZF, and Maier U: The impact of ejaculation on serum prostate specific antigen. J Urol 150: 895-897, 1993.
41. Sinha AA, Gleason DF, Wilson MJ, Staley NA, Furcht LT, Palm SL, Reddy PK, Sibley RK, and Martinez-Hernandez A: Immunohistochemical localization of laminin in the basement membranes of normal, hyperplastic and neoplastic human prostate. The Prostate 15: 299-313, 1989.
42. Krauer KG, McKenzie IFC, and Pietersz GA: Antitumor effect of 2'-deoxy-5-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts. Cancer Res 32: 132-137, 1992.
43. Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes JM: The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 52: 835-842, 1992.
44. Pietersz GA, and Krauer K: Antibody-targeted drugs for the therapy of cancer. J Drug Targeting 2: 183-215, 1994.